“Safe and Effective Pfizer Vaccine”: Food and Drug Administration report on drug. Green light during the week

The vaccine Pfizer is very “effective” in preventing COVID-19 and I find myself criteria necessary on the security front, without raising details worries. It is the opinion expressed by the Food and Drug Administration, which in an American report thus approves the drug against SARS-CoV-2. Last week the treatment received a green light from United Kingdom, where the population has already begun to receive it. The meeting where the Fda must give the go-ahead to the administration of the vaccine is expected in the week, while in Europe theMom – the drug agency in Brussels – will rule on December 29.

The report – According to the dossier of the Fda, anticipated by New York Times, the vaccine anti-Covid made by Pfizer in collaboration with the BioNTech demonstrates a strong immune response in the first 10 days after the administration of the first dose. Last month, Pfizer me BioNTech announced that their vaccine had a 95 percent efficacy rate after two doses administered three weeks apart. The new analyzes show that protection begins much earlier. In addition, it is specified in the relationship, the vaccine worked well regardless of ethnicity, from weight or from the age of voluntary. The study did not find serious problems Related to the vaccine, however, many experienced pain, fever, and other side effects. Thursday the Fda it will convene a kind of scientific tribunal that will discuss, in public and on live broadcast, how strong the data really is in support of the approval. A group of independent scientists will select the FDA’s first-step review before recommending the vaccine’s safety and efficacy to millions of Americans. The FDA, which normally follows the advice of the committee, is expected to issue a decision in the days following the review.

The effects of the vaccine during the trial. – If the green light is given, the first recipients of the vaccine would be health workers and residents of nursing homes, according to the plans established by each state. Pfizer and his german partner BioNTech had previously reported that vaccines appear to be 95% effective in preventing disease COVID-19 mild to severe in a large ongoing study. The claim is based on the first 170 infections found. Only eight of the infections later they emerged among the volunteers who had received the real vaccine, while the rest had received a dummy injection. Pfizer reported no serious side effects. Some recipients experience reactions flu-like, including fever, fatigue or muscle aches, especially after the required second dose. It is a sign that the system immune is getting high, able to recognize and fight the real virus if it appears. Emergency vaccinations could begin before the study of 44,000 people Pfizer it’s complete. The volunteers will be monitored for several years.